Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 2
2002 1
2003 1
2004 2
2005 2
2006 2
2007 2
2008 3
2009 1
2010 4
2011 5
2012 16
2013 13
2014 13
2015 14
2016 24
2017 33
2018 26
2019 31
2020 51
2021 43
2022 47
2023 48
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

322 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Malignant Bladder Neoplasm"
Page 1
Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials.
Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group. Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group. Eur Urol. 2022 Jan;81(1):50-61. doi: 10.1016/j.eururo.2021.09.028. Epub 2021 Nov 19. Eur Urol. 2022. PMID: 34802798 Free PMC article. Review.
CONCLUSIONS: This systematic review and meta-analysis demonstrates that cisplatin-based adjuvant chemotherapy is a valid option for improving outcomes for muscle-invasive bladder cancer. PATIENT SUMMARY: We looked at the effect of cisplatin-based chemotherapy on outcomes i …
CONCLUSIONS: This systematic review and meta-analysis demonstrates that cisplatin-based adjuvant chemotherapy is a valid option for improvin …
Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Compérat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, Lotan Y, Palou J, Gontero P, Babjuk M, Witjes JA, Kamat AM, Roupret M, Shariat SF, Pradere B; European Association of Urology–Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Laukhtina E, et al. Eur Urol Oncol. 2021 Dec;4(6):927-942. doi: 10.1016/j.euo.2021.10.003. Epub 2021 Nov 6. Eur Urol Oncol. 2021. PMID: 34753702 Free article. Review.
CONTEXT: During the past decade, several urinary biomarker tests (UBTs) for bladder cancer have been developed and made commercially available. ...The secondary endpoints were the diagnostic values for high-grade (HG) recurrence as well as for the initial det …
CONTEXT: During the past decade, several urinary biomarker tests (UBTs) for bladder cancer have been developed and made commer …
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.
Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM. Chang SS, et al. J Urol. 2016 Oct;196(4):1021-9. doi: 10.1016/j.juro.2016.06.049. Epub 2016 Jun 16. J Urol. 2016. PMID: 27317986 Review.
PURPOSE: Although associated with an overall favorable survival rate, the heterogeneity of non-muscle invasive bladder cancer (NMIBC) affects patients' rates of recurrence and progression. ...
PURPOSE: Although associated with an overall favorable survival rate, the heterogeneity of non-muscle invasive bladder cancer (NMIBC) …
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?
Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, De Nunzio C, Okamura K, Kaasinen E, Solsona E, Ali-El-Dein B, Tatar CA, Inman BA, N'Dow J, Oddens JR, Babjuk M. Sylvester RJ, et al. Eur Urol. 2016 Feb;69(2):231-44. doi: 10.1016/j.eururo.2015.05.050. Epub 2015 Jun 16. Eur Urol. 2016. PMID: 26091833 Review.
The instillation did not reduce recurrences in patients with a prior recurrence rate of more than one recurrence per year or in patients with an European Organization for Research and Treatment of Cancer (EORTC) recurrence score 5. ...PATIENT SUMMARY: …
The instillation did not reduce recurrences in patients with a prior recurrence rate of more than one recurrence per ye …
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Han MA, Maisch P, Jung JH, Hwang JE, Narayan V, Cleves A, Hwang EC, Dahm P. Han MA, et al. Cochrane Database Syst Rev. 2021 Jun 14;6(6):CD009294. doi: 10.1002/14651858.CD009294.pub3. Cochrane Database Syst Rev. 2021. PMID: 34125951 Free PMC article.
BACKGROUND: It remains unclear whether people with non-muscle invasive bladder cancer (NMIBC) benefit from intravesical gemcitabine compared to other agents in the primary or recurrent setting following transurethral resection of a bladder tumor. ...We are ve …
BACKGROUND: It remains unclear whether people with non-muscle invasive bladder cancer (NMIBC) benefit from intravesical gemcitabine c …
The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.
Fossati N, Willemse PM, Van den Broeck T, van den Bergh RCN, Yuan CY, Briers E, Bellmunt J, Bolla M, Cornford P, De Santis M, MacPepple E, Henry AM, Mason MD, Matveev VB, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Lam TB, Mottet N, Joniau S. Fossati N, et al. Eur Urol. 2017 Jul;72(1):84-109. doi: 10.1016/j.eururo.2016.12.003. Epub 2017 Jan 24. Eur Urol. 2017. PMID: 28126351 Free article. Review.
Conflicting results emerged when comparing biochemical and clinical recurrence, while no significant differences were observed among groups for survival. Conversely, the majority of studies showed that the more extensive the PLND, the greater the adverse outcomes in terms …
Conflicting results emerged when comparing biochemical and clinical recurrence, while no significant differences were observed among …
Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review.
Soorojebally Y, Neuzillet Y, Roumiguié M, Lamy PJ, Allory Y, Descotes F, Ferlicot S, Kassab-Chahmi D, Oudard S, Rébillard X, Roy C, Lebret T, Rouprêt M, Audenet F. Soorojebally Y, et al. World J Urol. 2023 Feb;41(2):345-359. doi: 10.1007/s00345-022-04253-3. Epub 2023 Jan 2. World J Urol. 2023. PMID: 36592175 Review.
OBJECTIVE: To perform a systematic review of data on the clinical validity and clinical utility of eleven urinary biomarkers (VisioCyt(), Xpert()Bladder, BTA stat(), BTA TRAK, NMP22 BC(), NMP22() BladderChek() Test, ImmunoCyt/uCyt1+, UroVysion Bladder Cancer …
OBJECTIVE: To perform a systematic review of data on the clinical validity and clinical utility of eleven urinary biomarkers (VisioCy …
Hyperthermia for non-muscle invasive bladder cancer.
Soria F, Allasia M, Oderda M, Gontero P. Soria F, et al. Expert Rev Anticancer Ther. 2016;16(3):313-21. doi: 10.1586/14737140.2016.1135743. Epub 2016 Jan 21. Expert Rev Anticancer Ther. 2016. PMID: 26713510 Review.
Recurrent non muscle invasive bladder cancer (NMIBC) represents a therapeutic challenge, especially in the case of Bacillus Calmette Guerin (BCG)-failures. ...Treatment with CHT is safe and quite well tolerated. CHT seems to be effective in low and intermediate risk …
Recurrent non muscle invasive bladder cancer (NMIBC) represents a therapeutic challenge, especially in the case of Bacillus Ca …
Treatment of muscle-invasive bladder cancer: A systematic review.
Chou R, Selph SS, Buckley DI, Gustafson KS, Griffin JC, Grusing SE, Gore JL. Chou R, et al. Cancer. 2016 Mar 15;122(6):842-51. doi: 10.1002/cncr.29843. Epub 2016 Jan 15. Cancer. 2016. PMID: 26773572 Free article. Review.
There is uncertainty regarding the use of bladder-sparing alternatives to standard radical cystectomy, optimal lymph node dissection techniques, and optimal chemotherapeutic regimens. This study was conducted to systematically review the benefits and harms of bladder …
There is uncertainty regarding the use of bladder-sparing alternatives to standard radical cystectomy, optimal lymph node dissection …
Blood-Based Biomarkers as Prognostic Factors of Recurrent Disease after Radical Cystectomy: A Systematic Review and Meta-Analysis.
Ofner H, Laukhtina E, Hassler MR, Shariat SF. Ofner H, et al. Int J Mol Sci. 2023 Mar 19;24(6):5846. doi: 10.3390/ijms24065846. Int J Mol Sci. 2023. PMID: 36982918 Free PMC article. Review.
Identification of the patients most likely to benefit from RC only versus a combination with systemic therapy versus systemic therapy first/only and bladder-sparing is needed. This systematic review and meta-analysis pools the data from published studies on blood-based bio …
Identification of the patients most likely to benefit from RC only versus a combination with systemic therapy versus systemic therapy first/ …
322 results